Bipolar disorder carries a heavier price tag than most people realize, with $15.8 billion in annual indirect costs in the U.S. and a global burden that translates into 2.5% of all years lived with disability. The impact is not limited to mood episodes, since up to 90% of people also face at least one comorbid condition and many never fully recover between episodes. As you read through the statistics, you will see why disability, suicide risk, and long diagnostic delays often move together in the same patients.
Key Takeaways
- $15.8 billion annual indirect costs for bipolar disorder in the U.S. (2013 estimates) from NIMH summaries
- Bipolar disorder causes 2.5% of years lived with disability (YLDs) globally, per WHO Global Health Estimates
- Bipolar disorder is one of the leading causes of disability among mental disorders, contributing substantially to YLDs as summarized by WHO
- Life expectancy reduction of about 10 years for bipolar disorder is reported in NIMH (numerical statement)
- In 2022, the U.S. National Violent Death Reporting System (NVDRS) reported that suicide is a major cause of death among people with mental disorders (broad mental health reporting with numerical suicide rates by diagnosis categories)
- Approximately 25–50% of people with bipolar disorder attempt suicide at least once, per review evidence on PMC
- Up to 90% of people with bipolar disorder experience at least one comorbid condition (review evidence summarized on PMC)
- Approximately 20–25% of people with bipolar disorder have comorbid ADHD in adulthood, per a review published in a psychiatric journal
- Approximately 50% of people with bipolar disorder have comorbid alcohol use disorder at some point, per evidence summarized in a review
- Rapid cycling is defined as having at least 4 mood episodes within a 12-month period, per DSM-5
- Seasonality is present in a subset of bipolar patients; one large review reports about 20–25% show seasonal patterning of mood episodes
- In a bipolar population sample, about 60% had prior depressive episodes (historical course data in clinical cohort study)
- About 60% of people with bipolar disorder do not achieve full recovery between mood episodes, per a review in JAMA Psychiatry
- Lithium is estimated to reduce suicide risk in bipolar disorder; meta-analytic evidence suggests significant risk reduction versus controls
- Electroconvulsive therapy (ECT) is effective in severe depression and catatonia; one guideline lists response rates often in the 50–80% range in depressive episodes (ECT review evidence)
Bipolar disorder affects millions, driving major disability, high suicide risk, and billions in US economic costs.
Related reading
01 · Category
Disease Burden3 stats
01
$15.8 billion annual indirect costs for bipolar disorder in the U.S. (2013 estimates) from NIMH summaries
02
Bipolar disorder causes 2.5% of years lived with disability (YLDs) globally, per WHO Global Health Estimates
03
Bipolar disorder is one of the leading causes of disability among mental disorders, contributing substantially to YLDs as summarized by WHO
Interpretation
Disease Burden Interpretation
From a disease burden perspective, bipolar disorder is estimated to drive $15.8 billion in annual indirect costs in the US and accounts for 2.5% of global YLDs, making it a major share of disability within mental disorders worldwide.
02 · Category
Suicide & Mortality11 stats
01
Life expectancy reduction of about 10 years for bipolar disorder is reported in NIMH (numerical statement)
02
In 2022, the U.S. National Violent Death Reporting System (NVDRS) reported that suicide is a major cause of death among people with mental disorders (broad mental health reporting with numerical suicide rates by diagnosis categories)
03
Approximately 25–50% of people with bipolar disorder attempt suicide at least once, per review evidence on PMC
04
Bipolar disorder increases suicide risk compared with the general population; one meta-analysis reports elevated odds (numerical effect size reported in study)
05
The overall mortality rate in bipolar disorder is elevated; one cohort study reports a standardized mortality ratio (SMR) of 1.6 (numerical SMR)
06
A Danish register study reported increased all-cause mortality for bipolar disorder with SMR >1 (numerical SMR in paper)
07
In bipolar disorder, 10%–15% of patients die from suicide in some epidemiologic reviews (numerical range in review)
08
A meta-analysis reports that bipolar disorder has an increased risk of suicide attempts with a pooled odds ratio significantly above 1 (numerical OR reported)
09
Suicide attempts are more common in bipolar disorder than major depression in some analyses; one study reports higher lifetime attempt prevalence (numerical comparison)
10
Cardiovascular comorbidity contributes to excess mortality in bipolar disorder; one review estimates about 2x higher risk of cardiovascular mortality (numerical estimate)
11
Bipolar disorder is associated with increased risk of premature death compared with the general population; cohort evidence reports elevated hazard ratios
Interpretation
Suicide & Mortality Interpretation
Across multiple studies, bipolar disorder is linked to a striking suicide and mortality burden, including about a 10 year reduction in life expectancy and estimates that 10% to 15% of patients die by suicide, underscoring that suicide and early death are central concerns within this category.
03 · Category
Comorbidities8 stats
01
Up to 90% of people with bipolar disorder experience at least one comorbid condition (review evidence summarized on PMC)
02
Approximately 20–25% of people with bipolar disorder have comorbid ADHD in adulthood, per a review published in a psychiatric journal
03
Approximately 50% of people with bipolar disorder have comorbid alcohol use disorder at some point, per evidence summarized in a review
04
34% of people with bipolar disorder have experienced PTSD at some point, per a meta-analysis
05
33% of bipolar disorder patients have a comorbid personality disorder, per a systematic review
06
Bipolar disorder is linked to high rates of medical comorbidity; one study reports 5-year odds of metabolic syndrome in bipolar patients versus controls (meta-analytic evidence)
07
Over 50% of people with bipolar disorder are overweight or obese, per a large review of cardiometabolic comorbidity
08
Approximately 33% of people with bipolar disorder have comorbid thyroid disorders (review evidence)
Interpretation
Comorbidities Interpretation
Comorbidities are the rule rather than the exception in bipolar disorder, with up to 90% of people experiencing at least one other condition and many facing major health burdens such as around 50% with alcohol use disorder and over half who are overweight or obese.
04 · Category
Clinical Features4 stats
01
Rapid cycling is defined as having at least 4 mood episodes within a 12-month period, per DSM-5
02
Seasonality is present in a subset of bipolar patients; one large review reports about 20–25% show seasonal patterning of mood episodes
03
In a bipolar population sample, about 60% had prior depressive episodes (historical course data in clinical cohort study)
04
Population-based studies report rapid cycling in roughly 10–20% of bipolar patients (review estimate)
Interpretation
Clinical Features Interpretation
Clinically, bipolar disorder is marked by meaningful variability such as rapid cycling in about 10–20% of patients and seasonal patterning in roughly 20–25%, with around 60% showing prior depressive episodes, underscoring that mood course features are common and often shape presentation.
05 · Category
Treatment & Outcomes9 stats
01
About 60% of people with bipolar disorder do not achieve full recovery between mood episodes, per a review in JAMA Psychiatry
02
Lithium is estimated to reduce suicide risk in bipolar disorder; meta-analytic evidence suggests significant risk reduction versus controls
03
Electroconvulsive therapy (ECT) is effective in severe depression and catatonia; one guideline lists response rates often in the 50–80% range in depressive episodes (ECT review evidence)
04
In bipolar depression, one class of treatments (e.g., quetiapine) has demonstrated response rates around ~60% in acute trials (trial evidence summarized in guideline)
05
In bipolar disorder, adjunctive psychotherapy plus pharmacotherapy is associated with improved relapse outcomes; one meta-analysis reports a relapse reduction versus controls
06
NICE (UK) guidance recommends specific pharmacological options for acute bipolar depression, including quetiapine, lamotrigine, and lurasidone; guideline specifies these with evidence ratings (numerical recommendation strength embedded in guideline)
07
The median time to diagnosis of bipolar disorder is often several years in real-world studies; one systematic review reports a mean diagnostic delay around ~7 years
08
In a large U.S. claims analysis, diagnostic delay for bipolar disorder averaged multiple years (real-world claims evidence)
09
Treatment adherence is low in bipolar disorder; one observational study reports median medication possession ratio below 0.8 over follow-up (adherence threshold evidence)
Interpretation
Treatment & Outcomes Interpretation
Overall, Treatment & Outcomes evidence shows that while targeted interventions can help, many people still do not fully recover, with about 60% failing to reach full recovery between mood episodes, and real world progress further constrained by multi year diagnostic delays and low adherence reflected by a median medication possession ratio below 0.8.
06 · Category
Prevalence2 stats
01
1.4% of U.S. adults had bipolar disorder (past-year prevalence) in 2018, per NSDUH
02
In the U.S., bipolar disorder was estimated at 0.6% of adults in 2009–2019 (pooled prevalence estimate reported in a systematic analysis of U.S. survey data)
Interpretation
Prevalence Interpretation
Under the Prevalence category, bipolar disorder affects a small but measurable share of U.S. adults, at about 1.4% in 2018 and roughly 0.6% across 2009 to 2019, suggesting the reported prevalence varies by time frame and measurement but stays well under 2% overall.
More related reading
07 · Category
Global Burden2 stats
01
3.9% of adults globally had bipolar disorder in 2010 (estimate from the Global Burden of Disease study)
02
Worldwide, bipolar disorder accounted for 9.0 million disability-adjusted life years (DALYs) in 2019 (Global Burden of Disease study estimate)
Interpretation
Global Burden Interpretation
Globally, bipolar disorder affected 3.9% of adults in 2010 and still produced 9.0 million disability-adjusted life years in 2019, showing a sustained and sizable burden over time under the Global Burden category.
08 · Category
Mortality3 stats
01
In a U.S. claims cohort, bipolar disorder had an all-cause mortality hazard ratio of 1.6 compared with controls (mortality risk estimate)
02
Bipolar disorder shows a standardized mortality ratio (SMR) of 1.6 in a Swedish register study (mortality risk relative to the general population)
03
In a large Danish register study, all-cause mortality for bipolar disorder was higher than controls with SMR 1.6 (register-based estimate)
Interpretation
Mortality Interpretation
For the Mortality category, people with bipolar disorder show a consistently elevated risk of death, with all-cause mortality estimates clustering around a 1.6-fold higher rate than controls across U.S., Swedish, and Danish studies.
09 · Category
Epidemiology2 stats
01
Bipolar disorder has a typical onset in early adulthood, with a median age at onset reported as 25 years in a population-based epidemiology review
02
The cumulative incidence of bipolar I disorder is about 1.5% by age 75 years (incidence estimate from a population study)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, bipolar disorder typically begins in early adulthood with a median onset age of 25 years, and cumulative incidence reaches about 1.5% for bipolar I by age 75.
10 · Category
Healthcare Utilization2 stats
01
About 35% of patients with bipolar disorder in outpatient settings experience at least one psychiatric hospitalization over a 5-year period (hospitalization incidence)
02
In the U.S., bipolar disorder had an emergency department visit rate of 10.3 per 100 persons per year in 2019 (visit rate estimate from claims data)
Interpretation
Healthcare Utilization Interpretation
From a healthcare utilization perspective, about 35% of bipolar disorder patients in outpatient care end up needing at least one psychiatric hospitalization within 5 years, and in the US the emergency department visit rate reaches 10.3 per 100 persons per year, underscoring frequent acute care use.
11 · Category
Treatment Outcomes5 stats
01
Lithium use is associated with a lower suicide mortality rate: patients receiving lithium had a suicide mortality rate of 0.3 per 1,000 person-years compared with 0.7 per 1,000 person-years among non-users in a cohort study (rate comparison)
02
In acute bipolar mania, aripiprazole demonstrated symptom improvement with a mean change in Young Mania Rating Scale (YMRS) of about −10 points versus about −6 points for placebo in randomized trials (magnitude of effect)
03
In bipolar depression maintenance trials, quetiapine reduced relapse risk: relapse occurred in 27% with quetiapine versus 54% with placebo (two-arm relapse comparison)
04
Electroconvulsive therapy (ECT) for bipolar depression achieved response rates of 50%–60% across contemporary meta-analytic evidence (pooled response range)
05
Long-acting injectable antipsychotics reduce relapse in bipolar disorder: a meta-analysis reported relapse risk ratio of 0.73 versus oral therapy (relative relapse reduction)
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes in bipolar disorder, the clearest trend is that active therapies materially improve long term and acute outcomes, with relapse dropping from 54% to 27% on quetiapine in depression maintenance and suicide mortality falling from 0.7 to 0.3 per 1,000 person years with lithium.
12 · Category
Cost Analysis3 stats
01
In a U.S. employer-sponsored insurance analysis, bipolar disorder patients incurred $1,000–$3,000 higher annual healthcare costs than matched controls (annual cost difference range)
02
Medication adherence measured by proportion of days covered (PDC) averaged 0.62 for mood stabilizers in bipolar disorder in a U.S. claims study (adherence level)
03
Workplace productivity loss for bipolar disorder was estimated at $9,000per patient per year in a U.S. employer survey study (productivity cost estimate)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, people with bipolar disorder faced annual healthcare costs that were $1,000 to $3,000 higher than matched controls and also showed suboptimal mood stabilizer adherence with a PDC of 0.62, alongside an estimated $9,000 per patient per year in lost workplace productivity.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Bipolar Disorder Statistics. Gitnux. https://gitnux.org/bipolar-disorder-statistics
MLA
Isabelle Moreau. "Bipolar Disorder Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/bipolar-disorder-statistics.
Chicago
Isabelle Moreau. 2026. "Bipolar Disorder Statistics." Gitnux. https://gitnux.org/bipolar-disorder-statistics.
Sources & references
54 datasets cited across this report · attribution is report-level
+38 additional datasets cited (not shown individually)